Global

Oct 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Sir Michael Rawlins, Chairman of the UK National Institute for Health and Clinical Excellence
Oct 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Y.K. Hamied, PhD, Chairman, Cipla
Aug 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.
Aug 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
When it comes to the emerging markets, executing a few key elements of success are more important than ever.
Jul 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy
Jun 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Why has the EU still not managed to update its rules on information about medicines?
May 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The EU is largely powerless when it comes to policies over pricing and reimbursement
May 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance
Jul 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.
May 01, 2010
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The three-way race for control of Parliament leaves the future of the British pharmaceutical industry in the balance.
native1_300x100
lorem ipsum